In addition, the multi-drug, biomarker-directed, phase II platform ORCHARD trial (NCT03944772) is ongoing and evaluating resistance mechanisms and combination treatment options for patients with EGFR-mutant NSCLC who have progressed on first-line osimertinib therapy, including osimertinib and savolitinib, for patients with acquired MET amplification. Here, MET is linked to non-small cell lung carcinoma.